Xencor

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xencor reports strong earnings, focuses on innovative pipeline strategies

Xencor's strong financial performance and promising pipeline programs position it well for growth
Unique mechanisms and designs offer competitive advantages in oncology and autoimmune disease treatments
Challenges like revenue expectations and validation requirements are being addressed strategically
Opportunities for collaborations and program optimizations pave the way for future success

Xencor advances internal portfolio with strategic focus on impactful targets

Xencor's Q1 2023 Earnings Call highlighted progress in their internal development portfolio, welcoming a new Chief Development Officer and emphasizing innovative therapeutic formats.
While facing challenges in data updates and program differentiation, the company's strategic focus on impactful targets and early clinical development positions them for future success.
Opportunities lie in expanding therapeutic programs, leveraging royalties, and exploring new avenues for growth, signaling a promising trajectory for Xencor in the biopharmaceutical landscape.

Xencor reports robust Q2 earnings and pipeline advancements

Xencor's Q2 2023 earnings call showcased strong performance in royalties and collaborations
The company's diverse pipeline and focus on safety and selectivity present opportunities
Challenges include addressing safety concerns and finalizing regimen for advancement
Overall, Xencor remains optimistic about future updates and pipeline progress

Xencor reports robust Q3 earnings, advances novel oncology therapeutics

Xencor's Q3 earnings call highlighted a strong financial performance, strategic pipeline adjustments, and progress in developing novel antibody-based therapeutics for oncology. The company is focused on maintaining asset potential through royalty deals and advancing internal pipeline candidates targeting solid tumors.

Xencor reports robust clinical data for vudalimab in prostate cancer

Xencor's Q4 earnings call showcased strong clinical data for vudalimab in prostate cancer, highlighting its efficacy and safety profile. The company's strategic focus on T-cell engagers and XmAb bispecific technology positions it well for future growth and innovation in solid tumor targeting.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

MONROVIA, Calif.--( BUSINESS WIRE )--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

IRVING, Texas and MONROVIA, Calif. , Jan. 5, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer.

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates

MONROVIA, Calif.--( BUSINESS WIRE )--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.

Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference

MONROVIA, Calif.--( BUSINESS WIRE )--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poster session today from 6:00 p.m. to 8:00 p.m. CST at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana.

Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting

The consensus price target hints at a 69.3% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect?

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Xencor (XNCR) Upgraded to Buy: Here's What You Should Know

The mean of analysts' price targets for Xencor (XNCR) points to a 74.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?

Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

Xencor, Inc. (NASDAQ:XNCR ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President & CEO John Kuch - CFO John Desjarlais - Chief Scientific Officer Allen Yang - Chief Medical Officer Ralph Stitnick - Executive Medical Director & Head of Autoimmune Conference Call Participants Edward Tenthoff - Piper Sandler Mara Goldstein - Mizuho Jonathan Chang - SVB Securities Brian Cheng - JP Morgan Dane Leone - Raymond James Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets David Dai - SMBC Charles Zhu - Guggenheim Securities Peter Lawson - Barclays Zhiqiang Shu - Berenberg Operator Good day, and thank you for standing by. Welcome to the Xencor Q3 2022 Conference Call.

Xencor, Inc. (XNCR) Q3 2022 Earnings Call Transcript

Xencor Reports Third Quarter 2022 Financial Results

Xencor's IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin's Lymphoma at the American Society of Hematology Annual Meeting

Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022

PARIS--(BUSINESS WIRE)--SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (

SpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Begun

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Boston, November 10-12, 2022. Data from the first patients enrolled in a Phase 2 study of vudalimab, Xencor's selective PD-1 x CTLA-4 bispecific antibody, plus chemo

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to its board of directors. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently served as a senior vice president at Genentech, a member of the Roche Group, and as it

Xencor Appoints Nancy Valente, M.D., to Board of Directors

Xencor, Inc. (NASDAQ:XNCR ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President and CEO Allen Yang - CMO John Kuch - CFO John Desjarlais - CSO Conference Call Participants Mara Goldstein - Mizuho David Dai - SMBC Kaveri Pohlman - BTIG Charles Zhu - Guggenheim Partners Edward Tenthoff - Piper Sandler Xinyu Liu - RBC Capital Markets Etzer Darout - BMO David Nierengarten - Wedbush Bill Maughan - Canaccord Genuity Operator Good afternoon. Thank you for standing by and welcome to the Xencor's Second Quarter 2022 Conference Call.

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2022 Results Earnings Call Transcript

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2022 and provided a review of recent business and clinical highlights. “Xencor is applying our leading protein engineering tools and proprietary XmAb technologies to create a broad portfolio of novel bispecific antibodies

Xencor Reports Second Quarter 2022 Financial Results

IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced today a multi-year strategic option and license agreement to research, develop and commercialize XmAb® bispecific antibodies directed against novel targets for the treatment of patients with cancer.

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after the market closes on Wednesday, August 3, 2022. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. T

Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022

Shares of Xencor have fallen by 46% since my 2019 update. I initially liked this one for "picks and shovels" aspect of the story. XmAb technology is being utilized by a variety of big pharmaceutical companies, with focus on bispecific antibodies and engineered cytokines.

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). These results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), during the pos

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Emergent BioSolutions

Jack in the Box

Monro

Patrick Industries

Shutterstock

Ultra Clean

Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. The post 7 High-Risk, High-Reward Small-Cap Stocks to Buy Now appeared first on InvestorPlace.

7 High-Risk, High-Reward Small-Cap Stocks to Buy Now

Xencor, Inc. (NASDAQ:XNCR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Jonathan Chang - SVB Securities Supawat Thongthip - Mizuho Dane Leone - Raymond James Charles Zhu - Guggenheim Securities Etzer Darout - BMO Capital Markets Xinyu Liu - RBC Capital Markets Zhiqiang Shu - Berenberg David Dai - SMBC David Nierengarten - Wedbush Securities Operator Good afternoon, ladies and gentlemen and thank you for standing by and welcome to the Xencor's First Quarter 2022 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2022 Results - Earnings Call Transcript

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Xencor Stock (XNCR)